DarioHealth Corp. (DRIO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerning factors: a 14.3% revenue decline, delayed cash flow breakeven, and client onboarding issues. Despite cost reductions and improved gross margins, the strategic shift to a SaaS model and competitive pressures pose risks. Q&A highlights management's unclear responses on financial impacts, further contributing to uncertainty. These factors suggest a negative sentiment, likely impacting the stock price negatively in the short term.
Key Financial Performance
Total Revenue $5.4 million for Q2 2025, compared to $6.3 million in Q2 2024 (a decrease of 14.3%) and $6.8 million in Q1 2025. The decline is attributed to the nonrenewal of a large national health plan earlier this year and a strategic shift towards a SaaS-like recurring revenue model.
GAAP Gross Margin 55% in Q2 2025, up from 44% in Q2 2024 (an increase of 11 percentage points). This improvement reflects the company's focus on sustainable ARR and operational efficiencies.
Non-GAAP Gross Margin (B2B2C) Approximately 80% since Q1 2024, demonstrating the efficiency of the business model.
Operating Expenses $12.2 million in Q2 2025, down 36% from $18.9 million in Q2 2024. The reduction is due to post-merger integration, operational efficiencies, offshore initiatives, and AI-enabled efficiencies.
Operating Loss $9.2 million in Q2 2025, narrowed by 43% from $16.2 million in Q2 2024. This improvement is driven by reduced operating expenses and efficiency measures.
Cash and Short-term Deposits $22.1 million at the end of Q2 2025, supported by recent debt restructuring, providing additional flexibility for execution.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Multi-condition platform: DarioHealth's platform integrates chronic condition management, behavioral reinforcement, and personalized digital engagement, delivering a 5x ROI and medical cost reductions exceeding $5,000 per engaged user.
GLP-1 support program: A digital utilization management solution for obesity and diabetes care, combining clinical oversight, behavioral reinforcement, and digital tools to control costs and improve outcomes.
Sleep health market entry: DarioHealth entered the $150 billion sleep health market through a partnership with GreenKey, addressing sleep apnea and related disorders with scalable solutions.
New client acquisition: Signed 21 new clients year-to-date, including 2 national health plans and 18 employer clients, with 80% being multi-condition programs.
Pipeline growth: Pipeline expanded to $53 million, with $5 million in newly committed annual recurring revenues and an additional $5 million in late-stage contracting.
Health plan partnerships: Partnerships with over 25 qualified health plans for 2026, up from 3 in the previous year, including 2 national-scale cardiometabolic accounts.
Gross margin improvement: GAAP gross margin increased to 55% from 44% year-over-year, with B2B2C business maintaining over 80% gross margins on a non-GAAP basis.
Operating expense reduction: Reduced GAAP operating expenses by 36% year-over-year, narrowing operating loss by 43%.
AI integration: Leveraging AI for operational efficiency, member engagement, and cost reduction, with a 15% reduction in operating expenses expected over the next 12-15 months.
Shift to recurring revenue model: Transitioned from one-time revenues to a SaaS-like recurring revenue model, focusing on sustainable ARR.
Channel partner optimization: Restructured channel partner contracts to align with market models, revitalizing partnerships and improving value propositions.
AI-powered operations: Embedded AI across operations to streamline processes, enhance engagement, and support scalable ROI models for chronic population management.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Gap: The company experienced a revenue gap due to slower-than-expected ramp-up of new accounts and onboarding of new logos. This was compounded by the nonrenewal of a large national health plan earlier in the year.
Cash Flow Breakeven Delay: The timeline for achieving cash flow breakeven has been extended by 12 to 15 months, now expected by the end of 2026 to early 2027.
Shift in Revenue Model: The strategic shift towards a SaaS-like recurring revenue model has led to short-term revenue declines, impacting financial performance.
Client Onboarding Delays: Several large accounts signed in 2025 are onboarding slower than anticipated, delaying revenue realization.
Market Competition: The competitive nature of the digital health industry poses risks to maintaining and growing market share.
Economic Uncertainty: Economic uncertainties could impact demand for the company's solutions and overall financial performance.
Dependence on Partnerships: The company’s growth strategy heavily relies on partnerships with health plans, PBMs, and benefit consultants, which could pose risks if these relationships do not perform as expected.
Operational Efficiency Challenges: While AI is being leveraged for operational efficiency, achieving the targeted 15% cost reduction in OpEx over the next 12 to 15 months remains a challenge.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Gap and Growth Acceleration: The company experienced a revenue gap due to slower-than-expected ramp-up of new accounts and onboarding of new logos. However, the full impact of several large accounts signed in 2025 will be felt more meaningfully at the end of 2025 and into 2026. The company remains confident that the short-term gap will be closed and growth will accelerate.
Cash Flow Breakeven: The timeline for achieving cash flow breakeven has been adjusted by approximately 12 to 15 months, now expected by the end of 2026 to the beginning of 2027.
New Clients and Pipeline: The company has signed 21 new clients year-to-date and remains on track to meet its goal of 40 by the end of the year. The pipeline has grown to $53 million, with over $5 million in final stages towards committed annual recurring revenue (CARR).
Health Plan Partnerships: Two health plans with national scale, representing multi-million dollar opportunities, are advancing evaluations for 2026 implementation. One of these is set to launch in the second half of 2025, contributing revenue in 2025 and building momentum for 2026.
Employer Segment Growth: The company is in final stages of clinical review with the largest employer in its history, representing 125,000 employees, for a January 2026 launch of its diabetes and hypertension offering. Accelerated RFP volume from benefit brokers is opening doors to high-value employers ahead of the 2026 plan year.
Pharma Business Transformation: The pharma business is transitioning from one-time revenues to recurring revenues. A few top accounts, including Sanofi, are expected to move to full commercial stage with recurring revenues.
Expansion into Sleep Health Market: The company entered the $150 billion sleep health market through a partnership with GreenKey, extending its platform into sleep apnea and related disorders. The first client in this category is expected to be signed in the near term.
AI Integration and Operational Efficiency: AI integration is expected to deliver approximately 15% cost reductions in operating expenses over the next 12 to 15 months. AI is also enhancing member engagement and driving measurable improvements in outcomes.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Was there any churn that contributed to the sequential revenue decline in Q2?
A:No, there was no churn in the ARR of the company. The decline was due to a one-time revenue in Q1 that did not repeat in Q2 and the loss of a big health plan. The company has 85% retention on clients and members year-over-year.
Q:Can you provide more details on the services discontinued by the health plan?
A:The health plan discontinued a Medicaid maternity program and in-sourced it. This decision was based on their preference to handle the work internally. The program had proven a good ROI for them.
Q:What differentiates the reduction in the health plan from the wins in the second half, and why should we not expect others to reduce scale?
A:The reduction was due to a non-renewed contract from the Twill business, which was a large deal but not indicative of a trend. The company has a diversified client base with no significant concentration. They are optimistic about new large accounts with national distribution, which are expected to positively impact revenues.
Q:How has the partnership program been restructured, and what are the positive impacts?
A:The company has focused on its 5 core conditions and expanded into areas like sleep apnea through partnerships. They aim to strategically add conditions and extend their reach for new revenue opportunities. Partnerships like Rula Health are helping to add virtual care services.
Q:What are the initiatives for reducing OpEx through AI, and what is the expected impact?
A:The company is aggressively adopting AI to reduce costs, including role duplication, offshoring, and AI agents. They plan to reduce OpEx by 15% over the next year, targeting areas like member management, enrollment, retention, G&A, and sales and marketing. The goal is to bring OpEx to around $8 million per quarter by the end of next year.
Q:What is the purpose and benefit of adding claims-based billing infrastructure?
A:The claims-based billing infrastructure allows the company to shift from engagement billing through administrative budgets to billing through claims and premiums. This opens up a larger revenue path and aligns with industry practices, enabling access to a significant profit pool.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific financial impact of the health plan loss and the exact timeline for achieving cash flow improvements through AI initiatives. Their responses lacked detailed numerical data and clarity in these areas.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARR
CARR
CFO
Corporate
Financial
GLP medication
GreenKey
Nelson President
President Chief
Research
Tuesday
benefit consultant
category
change
channel partner
client quality
consultant channel
contracting
core BBC
cost care
cycle
date
efficiency AI
example
expansion account
gap
health care
integration efficiency
logo
margin
number revenue
obesity diabetes
pillar
plan self
ramp
reinforcement
relapse
review
sleep apnea
utilization
weight
yield
DRIO Transcript
DarioHealth Corp. (DRIO) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals a focus on future growth and profitability, with expected revenue contributions from 2025 accounts and a path to breakeven by mid-2027. However, the lack of specific financial figures and uncertainty in achieving these milestones pose risks. No new partnerships or strong financial metrics were highlighted, and there was no mention of shareholder returns. Without clear guidance or immediate catalysts, the stock is likely to remain stable, resulting in a neutral prediction.
Sylogist Ltd. (SYZ:CA) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call presents mixed signals: while there are positive elements like improved recurring revenue gross margins and strategic partnerships, there are concerns about project service margins turning negative and soft SaaS ARR bookings due to timing issues. The Q&A reveals uncertainties about growth and margin progression, with management avoiding specific timelines. Despite a strong pipeline and transformational efforts, the lack of concrete guidance and ongoing transition phase temper overall optimism, suggesting a neutral stock price movement in the short term.
DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
Positive3-19
Despite a revenue decline due to a legacy client nonrenewal, the company shows strong operational efficiency with reduced expenses and improved margins. Strategic partnerships with major health plans and a growing pipeline indicate future growth potential. The Q&A session highlighted confidence in meeting analyst expectations and achieving cash flow positivity. The company's proactive cost management and strategic partnerships are positive indicators, despite economic uncertainties and competitive pressures. Overall, these factors suggest a positive sentiment towards stock performance in the short term.
DarioHealth Corp. (DRIO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call summary presents a mixed picture. Financial performance shows improvement in gross margins and operating losses, but revenue declined, raising concerns. Product development and market strategy are positive, with new partnerships and client growth. However, cash flow breakeven delay and lack of specific guidance in Q&A dampen optimism. Shareholder returns weren't discussed. Overall, the sentiment is neutral, reflecting balanced positive and negative factors.
DRIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
